Katsuro Tachibana

Prof. Dr. Katsuro Tachibana

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2002 in Circulation
Verified
Journal Article
Closed access
PDF file
YTYoshiaki Taniyama
Yoshiaki Taniyama
Katsuro TachibanaKatsuro Tachibana
Katsuro Tachibana
KHKazuya Hiraoka
Kazuya Hiraoka
TNTsunetatsu Namba
Tsunetatsu Namba
KYKeita Yamasaki
Keita Yamasaki
RMRyuichi Morishita
Ryuichi Morishita
Background — Although viral vector systems are efficient to transfect foreign genes into blood vessels, safety issues remain in relation to human gene therapy. In this study, we examined the feasibility of a novel nonviral vector system by using high-frequency, low-intensity ultrasound irradiation for transfection into blood vessels. Methods and Results — Luciferase plasmid mixed with or without echo contrast microbubble (Optison) was transfected into cultured human vascular smooth muscle cells (VSMC) and endothelial cells (EC) with the use of ultrasound. Interestingly, luciferase activity was markedly increased in both cell types treated with Optison. We then transfected luciferase plasmid mixed with Optison by means of therapeutic ultrasound into rat artery. Two days after transfection, luciferase activity was significantly higher in carotid artery transfected with luciferase gene with Optison and ultrasound than with plasmid alone. In addition, we transfected an anti-oncogene (p53) plasmid into carotid artery after balloon injury as a model of gene therapy for restenosis. Two weeks after transfection, the intimal-to-medial area ratio in rats transfected with wild-type p53 plasmid complexed with Optison by means of ultrasound was significantly decreased as compared with control, accompanied by a significant increase in p53 protein. No apparent toxicity such as inflammation could be detected in blood vessels transfected with plasmid DNA with ultrasound and Optison. Conclusions — Overall, we demonstrated that an ultrasound transfection method with Optison enhanced transfection efficiency of naked plasmid DNA into blood vessels without any apparent toxicity. Transfection of p53 plasmid with the use of this method should be useful for safe clinical gene therapy without a viral vector system.

1 April 1999 in The Lancet
Verified
Journal Article
Closed access
Katsuro TachibanaKatsuro Tachibana
Katsuro Tachibana
TUToshiki Uchida
Toshiki Uchida
KOKoichi Ogawa
Koichi Ogawa
NYNobuya Yamashita
Nobuya Yamashita
KTKazuo Tamura
Kazuo Tamura

1 September 1995 in Circulation
Verified
Journal Article
Closed access
Katsuro TachibanaKatsuro Tachibana
Katsuro Tachibana
STShunro Tachibana
Shunro Tachibana
Background Recent findings suggest that acoustic cavitation is responsible for acceleration of thrombolysis by ultrasound (US) energy. It is known that albumin microbubbles lower the threshold of acoustic cavitation production. Methods and Results The present study was designed to determine whether the presence of albumin microbubbles used for echo-contrast material (Albunex) can further accelerate fibrinolysis by US. Artificial thrombus was produced by Chandler’s loop method with blood extracted from a healthy subject. Urokinase (UK, 1200 IU/mL) was added to the artificial thrombi placed in test tubes. Each thrombus was exposed to US (170 kHz) at a distance of 1.2 cm for a total of 60 seconds at an intensity of 0.5 W/cm 2 at intervals of 2 seconds on and 4 seconds off. Echo-contrast material (0.6×10 6 microspheres per mL) or 5% albumin (for control) was circulated near the thrombus at a rate of 1 mL/min during the US exposure. Fibrinolysis was later determined by percentage of weight loss of thrombus after 60 minutes of incubation (n=15). Fibrinolysis with UK alone was 26.6±4.8%. Fibrinolysis with UK+US treatment was 33.3±5.8%. Further increase of fibrinolysis to 51.3±7.7% occurred in the presence of Albunex (UK+US+Albunex). Statistical differences were obtained between all these groups (ANOVA). Conclusions The presence of the echo-contrast agent induced further acceleration of thrombolysis by US energy. It is suggested that this diagnostic echo-contrast material can be used as an alternative therapeutic US drug enhancer for thrombolysis.

1 August 2008 in Ultrasonics
Verified
Journal Article
Closed access
Katsuro TachibanaKatsuro Tachibana
Katsuro Tachibana
LFLoreto B. Feril
Loreto B. Feril
YIYurika Ikeda-Dantsuji
Yurika Ikeda-Dantsuji

1 November 2003 in Radiology
Verified
Journal Article
Closed access
TLTieli Li
Tieli Li
Katsuro TachibanaKatsuro Tachibana
Katsuro Tachibana
MKMotomu Kuroki
Motomu Kuroki
MKMasahide Kuroki
Masahide Kuroki
To determine if commercially available echo-enhanced microbubble contrast agents could be used to increase gene transfection efficiency by means of relatively low-intensity ultrasound-mediated microbubble destruction in skeletal muscles. Three types of ultrasound microbubble contrast agents (0.01 mL of albumin [Albunex] and human albumin [Optison] and 10 mg/mL of SH U 508A [Levovist]) were each separately mixed with the reporter plasmid DNA (25 microg) encoding green fluorescent protein (GFP) prior to intramuscular injection into the quadriceps muscle of a mouse thigh bilaterally (seven mice per contrast agent). One of the muscle sites that was injected with plasmid DNA was irradiated with low-intensity therapeutic ultrasound (1 MHz) at an intensity of 2.0 W/cm2 for 2 minutes. Mice were sacrificed 7 days after ultrasound treatment for gene expression assay. The number of GFP-expressing muscle fibers was counted. Statistical significance was determined with a two-tailed Student t test. P <.05 was considered to indicate statistically significant difference. Muscle tissue exposed to ultrasound with air-filled Albunex or Levovist microbubbles revealed no difference in the number of GFP-expressing muscle fibers compared with the control non-ultrasound-exposed muscle. Albumin-coated octafluoropropane gas-filled Optison microbubbles showed a 10-fold increase in the number of GFP-expressing fibers (P <.05). Low-intensity ultrasound with echo-enhanced Optison induced efficient gene transfer unlike that with Albunex or Levovist.

1 January 2011 in Journal of Controlled Release
Verified
Journal Article
Closed access
YHYoshimi Harada
Yoshimi Harada
KOKoichi Ogawa
Koichi Ogawa
YIYutaka Irie
Yutaka Irie
HEHitomi Endo
Hitomi Endo
LFLoreto B. Feril
Loreto B. Feril
Katsuro TachibanaKatsuro Tachibana
Katsuro Tachibana